e-learning
resources
Vienna 2012
Monday, 03.09.2012
Early detection of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients
M. Peres Rangel, V. Karen de Sá, J.R. Maciel Martins, E.R. Parra Cuentas, R. Vieira Reis, A. Longatto Filho, T. Takagaki, H. Nader, V.L. Capelozzi (Sao Paulo, , Barretos, Brazil)
Source:
Annual Congress 2012 - Early detection of lung cancer
Session:
Early detection of lung cancer
Session type:
Oral Presentation
Number:
1643
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Peres Rangel, V. Karen de Sá, J.R. Maciel Martins, E.R. Parra Cuentas, R. Vieira Reis, A. Longatto Filho, T. Takagaki, H. Nader, V.L. Capelozzi (Sao Paulo, , Barretos, Brazil). Hyaluronan: A novel sputum marker for the screening and diagnosis of lung cancer patients. Eur Respir J 2012; 40: Suppl. 56, 1643
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
A 62-year-old man with scanty mucoid sputum
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Induced sputum in the diagnosis of lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 299s
Year: 2004
Screening and diagnosis of lung cancer
Source: Annual Congress 2013 –ERS/The Lancet/The Lancet Respiratory Medicine joint Lunchtime session on lung cancer
Year: 2013
Potential diagnostic markers in bronquial fluid of patients with non small cell lung cancer (NSCLC)
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Validation of diagnostic molecular markers in bronchial fluid for lung cancer
Source: Annual Congress 2011 - Progress in endoscopy for the diagnosis of lung cancer
Year: 2011
The evaluation of lung cancer patients
Source: Eur Respir J 2005; 26: Suppl. 49, 323s
Year: 2005
The diagnostic relevance of cytologic examination of induced sputum in lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 299s
Year: 2004
Shox2, a biomarker for confirming malignancy in bronchial lavage from patients with suspected lung cancer and inconclusive cytology
Source: Annual Congress 2009 - Diagnosis and treatment of lung cancer
Year: 2009
Dealys in the diagnosis and treatment of lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 458s
Year: 2004
The clinical value of autofluorescence bronchoscopy for the diagnosis of lung cancer
Source: Eur Respir J 2006; 28: 915-919
Year: 2006
Lung nodules in a lung cancer screening program: incidence density of lung cancer in patients with COPD and/or emphysema
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009
Screening for lung cancer
Source: Eur Respir Mon; 2009: 44: 57–70
Year: 2009
Lung function testing for the preoperative evaluation of patients with lung cancer
Source: Annual Congress 2003 - Lung function testing for preoperative evaluation in lung cancer patients
Year: 2003
Comparison of induced and spontaneous sputum in the diagnosis of lung cancer
Source: Eur Respir J 2001; 18: Suppl. 33, 64s
Year: 2001
Prevalence and characterization of interstitial lung disease in a lung cancer screening program
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Are there potential characteristical markers in bronquial fluid for diagnosis of small cell lung cancer (SCLC)?
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Early detection of lung cancer: role of biomarkers
Source: Eur Respir J 2003; 21: 36S-44S
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept